Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions

Open access

Abstract

Cancer's staggering molecular heterogeneity demands innovative approaches beyond traditional single-omics methods. The integration of multi-omics data, spanning genomics, transcriptomics, proteomics, metabolomics and radiomics, can improve diagnostic and prognostic accuracy when accompanied by rigorous preprocessing and external validation; for example, recent integrated classifiers report AUCs around 0.81-0.87 for difficult early-detection tasks. This review synthesizes how artificial intelligence (AI), particularly deep learning and machine learning, bridges this gap by enabling scalable, non-linear integration of disparate omics layers into clinically actionable insights. We explore cutting-edge AI methodologies, including graph neural networks for biological network modeling, transformers for cross-modal fusion, and explainable AI (XAI) for transparent clinical decision support. Critical applications are highlighted, such as AI-driven therapy selection (e.g., predicting targeted therapy resistance), proteogenomic early detection, and radiogenomic non-invasive diagnostics. We further address translational challenges: data harmonization, batch correction, missing data imputation, and computational scalability. Emerging trends, federated learning for privacy-preserving collaboration, spatial/single-cell omics for microenvironment decoding, quantum computing, and patient-centric "N-of-1" models, signal a paradigm shift toward dynamic, personalized cancer management. Despite persistent hurdles in model generalizability, ethical equity, and regulatory alignment, AI-powered multi-omics integration promises to transform precision oncology from reactive population-based approaches to proactive, individualized care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10238-025-01965-9

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Core omics layers in precision oncology
Fig. 1 Core omics layers in precision oncologyCC BY-NC-ND · PubMed Central
Fig. 2 End-to-end AI-driven multi-omics workflow for precision oncology. A recommended practical pipeline that summarizes best practices described in Sect. 4: start with multi-source data generation (NGS, MS proteomics, spatial transcriptomics, imaging, EHR), apply per-sample QC and read-depth/sample filters, then harmonize and correct batch effects (e.g., ComBat-seq or domain-adversarial encoders) with PCA/UMAP diagnostics; handle missingness with modern generative imputers (e.g., MIWAE/GANs) while reporting masking/imputation performance; choose a fusion strategy (early / hybrid / late) appropriate to data synchronicity and sample size; perform nested feature selection and cross-validation during model training; evaluate external generalizability with center/platform holdouts; and finally specify prospective evaluation and regulatory/monitoring plans (predetermined change-control, post-market calibration drift monitoring)
Fig. 2 End-to-end AI-driven multi-omics workflow for precision oncology. A recommended practical pipeline that summarizes best practices described in Sect. 4: start with multi-source data generation (NGS, MS proteomics, spatial transcriptomics, imaging, EHR), apply per-sample QC and read-depth/sample filters, then harmonize and correct batch effects (e.g., ComBat-seq or domain-adversarial encoders) with PCA/UMAP diagnostics; handle missingness with modern generative imputers (e.g., MIWAE/GANs) while reporting masking/imputation performance; choose a fusion strategy (early / hybrid / late) appropriate to data synchronicity and sample size; perform nested feature selection and cross-validation during model training; evaluate external generalizability with center/platform holdouts; and finally specify prospective evaluation and regulatory/monitoring plans (predetermined change-control, post-market calibration drift monitoring)CC BY-NC-ND · PubMed Central
Fig. 3 AI-driven multi-omics integration for precision immunotherapy. This conceptual workflow illustrates how artificial intelligence integrates diverse multi-omics data to recognize novel biomarkers, characterize mechanisms of therapy resistance (e.g., to Anti-PD-L1), and ultimately stratify patients into predicting responders and non-responders, paving the way for bit-specific antibody therapies and personalized CAR-T cell applications in precision oncology
Fig. 3 AI-driven multi-omics integration for precision immunotherapy. This conceptual workflow illustrates how artificial intelligence integrates diverse multi-omics data to recognize novel biomarkers, characterize mechanisms of therapy resistance (e.g., to Anti-PD-L1), and ultimately stratify patients into predicting responders and non-responders, paving the way for bit-specific antibody therapies and personalized CAR-T cell applications in precision oncologyCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Research works printed but not linked: 10

  1. Camps J, et al. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167841. · DOI
  2. Shmmon, Ahmad (2024) The Role of Artificial Intelligence in Diagnosing Malignant Tumors Eurasian Journal of Medicine and Oncology 281-294 10.14744/ejmo.2024.24486 · DOI
  3. Cai Z et al. Transformer-based deep learning integrates multi-omic data with cancer pathways. bioRxiv, 2024: p. 2022.10.27.514141. · DOI · Paper page
  4. Mohr AE, et al. Navigating challenges and opportunities in Multi-Omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496. · DOI · Paper page
  5. Sartori F et al. A comprehensive review of deep learning applications with Multi-Omics data in cancer research. Genes (Basel), 2025. 16(6). · DOI
  6. Shao Y, et al. Artificial Intelligence-Driven precision medicine: Multi-Omics and Spatial Multi-Omics approaches in diffuse large B-Cell lymphoma (DLBCL). Front Biosci (Landmark Ed). 2024;29(12):404. · DOI
  7. Mattei P-A, Frellsen J. MIWAE: Deep Generative Modelling and Imputation of Incomplete Data Sets. in International Conference on Machine Learning. 2019.
  8. Palmer DC, et al. GEMINI-NSCLC study: integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2025;43(16suppl):TPS8114–8114.
  9. Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol. 2025;16:1591696. · DOI
  10. Ferber D, et al. Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology. Nat Cancer. 2025;6(8):1337–49. · DOI · Paper page

Cited by

See all 140

Metadata

Authors
Hsu, C.-Y., Askar, S., Alshkarchy, S. S., Nayak, P. P., Attabi, K. A. L., Khan, M. A., Mayan, J. A., Sharma, M. K., Islomov, S., & Soleimani Samarkhazan, H.
Affiliations
  • Chia Nan University of Pharmacy and Science (TW)
  • Erbil Polytechnic University (IQ)
  • Al-Qasim Green University (IQ)
  • Siksha O Anusandhan University (IN)
  • Islamic University of Najaf (IQ)
  • Dhofar University (OM)
  • Sathyabama Institute of Science and Technology (IN)
  • Chaudhary Charan Singh University (IN)
Venue
Clinical and Experimental Medicine
Published
2025-11-21
Volume
26
Issue
1
Pages
29-29
ISSN
  • 1591-8890 (ISSN-L)
  • 1591-9528
OpenAlex
W4416442660
Cited by
140
References
74
Citations by year
2026: 136 · 2025: 4
FWCI
12.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical and Experimental Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
multi-omics integration, precision oncology, artificial intelligence in oncology, deep learning, graph neural networks, transformer models, cross-modal fusion, explainable AI, clinical decision support, radiogenomics, non-invasive cancer diagnosis, data harmonization, batch effect correction, missing data imputation, federated learning, single-cell omics, tumor microenvironment, quantum computing, model generalization
MeSH terms
Clinical Decision-Making, Machine Learning, Deep Learning, Multiomics, Artificial Intelligence, Humans, Medical Oncology, Neoplasms, Genomics, Proteomics, Metabolomics, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. https://app.cochat.ai/papers/10.1007/s10238-025-01965-9
The paper
Hsu, C.-Y., Askar, S., Alshkarchy, S. S., Nayak, P. P., Attabi, K. A. L., Khan, M. A., Mayan, J. A., Sharma, M. K., Islomov, S., & Soleimani Samarkhazan, H. (2025). AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01965-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.